<DOC>
	<DOC>NCT02607930</DOC>
	<brief_summary>The study will evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.</brief_summary>
	<brief_title>Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults</brief_title>
	<detailed_description />
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Key Antiretroviral treatment naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV1 infection) except the use for PrEP (preexposure prophylaxis) or PEP (postexposure prophylaxis), up to one month prior to screening Plasma HIV1 RNA levels ≥ 500 copies/mL at screening Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec) according to the CockcroftGault formula Negative screening test for HLAB*5701 allele provided by Gilead Sciences Key An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening (refer to study protocol) Decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal bleeding) Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance Females who are pregnant (as confirmed by positive serum pregnancy test) Females who are breastfeeding Chronic Hepatitis B Virus (HBV) infection Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>